Corcept Therapeutics Inc.

CORT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CORT Income Statement
CORT Balance Sheet
CORT Cash Flow
Congress Trading

Recent trades of CORT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CORT Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CORT Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CORT Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CORT's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Nov. 26, 2024
  • Patent Title: Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 19, 2024
  • Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Nov. 12, 2024
  • Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 12, 2024
  • Patent Title: Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers Oct. 08, 2024
  • Patent Title: Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators Oct. 01, 2024
  • Patent Title: Piperazine indazole glucocorticoid receptor antagonists Sep. 24, 2024
  • Patent Title: Bicyclic indazole glucocorticoid receptor antagonists Sep. 24, 2024
  • Patent Title: Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors Sep. 24, 2024
  • Patent Title: Pyrimidine cyclohexenyl glucocorticoid receptor modulators Jun. 25, 2024
  • Patent Title: Methods for shrinking pituitary tumors Jun. 11, 2024
  • Patent Title: Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors Apr. 30, 2024
  • Patent Title: Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Apr. 02, 2024
  • Patent Title: Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound Mar. 12, 2024
  • Patent Title: Methods of treating antipsychotic-induced weight gain with miricorilant Feb. 20, 2024
  • Patent Title: Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency Feb. 06, 2024
  • Patent Title: Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 28, 2023
  • Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Oct. 24, 2023
  • Patent Title: Quaternary indazole glucocorticoid receptor antagonists Oct. 17, 2023
  • Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Sep. 19, 2023
  • Patent Title: Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of cushing's syndrome patients Sep. 05, 2023
  • Patent Title: Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator Jun. 27, 2023
  • Patent Title: Glucocorticoid receptor modulators to treat cervical cancer May. 30, 2023
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators May. 16, 2023
  • Patent Title: Glucocorticoid receptor modulators to treat pancreatic cancer May. 09, 2023
  • Patent Title: Systems and methods of managing treatment of a chronic condition by symptom tracking Mar. 21, 2023
  • Patent Title: Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Feb. 28, 2023
  • Patent Title: Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator Feb. 28, 2023
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Feb. 14, 2023
  • Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Jan. 24, 2023
  • Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Jan. 10, 2023
  • Patent Title: Pyrimidine cyclohexenyl glucocorticoid receptor modulators Jan. 03, 2023
  • Patent Title: Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators Dec. 13, 2022
  • Patent Title: Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound Oct. 11, 2022
  • Patent Title: Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent Jul. 19, 2022
  • Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Jun. 28, 2022
  • Patent Title: Treatment and differential diagnosis of cushing's disease and ectopic cushing's syndrome May. 10, 2022
  • Patent Title: Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Mar. 29, 2022
  • Patent Title: Methods for treating cushing's syndrome Mar. 08, 2022
  • Patent Title: Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent Feb. 01, 2022
  • Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Jan. 04, 2022
  • Patent Title: Use of acth in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of cushing's syndrome patients Dec. 21, 2021
  • Patent Title: Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency Dec. 21, 2021
  • Patent Title: Optimizing mifepristone levels for cushing's patients Nov. 16, 2021
  • Patent Title: Treatment of muscular dystrophy Aug. 31, 2021
  • Patent Title: Method for differentially diagnosing acth-dependent cushing's syndrome Jul. 27, 2021
  • Patent Title: Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator Jul. 13, 2021
  • Patent Title: Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors Jun. 29, 2021
  • Patent Title: Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors Apr. 20, 2021
  • Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Apr. 13, 2021
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of CORT in WallStreetBets Daily Discussion

CORT News

Recent insights relating to CORT

CNBC Recommendations

Recent picks made for CORT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CORT

CORT Top Shareholders
Shareholder
Shares Held
CORT Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CORT Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CORT Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top